ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalidomide Maintenance After ASCT
ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalidomid…
2022年12月18日
vumedi.com
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7) | OncLive
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Thera…
2025年1月30日
onclive.com
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study | OncLive
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lena…
2022年12月22日
onclive.com
Daratumumab Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study | OncLive
5:53
Daratumumab Bortezomib/Lenalidomide/Dexameth…
2024年10月14日
onclive.com
Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma | OncLive
Dr Anderson on Daratumumab/Lenalidomide Mainten…
8 个月之前
onclive.com
Dr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 Study of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma | OncLive
Dr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 St…
2025年4月1日
onclive.com
ATLAS Trial Confirms Superior Myeloma Survival With KRd Maintenance | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
ATLAS Trial Confirms Superior Myeloma Survival With KRd Mainten…
2 周前
targetedonc.com
La FDA approuve le daratumumab et l'hyaluronidase-fihj associés au borté…
3 个月之前
zonebourse.com
3:58
Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL | OncLive
2025年2月4日
onclive.com
11:07
EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rit…
2024年1月23日
onclive.com
3:01
Next-Generation Therapies Target High-Risk Smoldering Multiple Myelo…
5 个月之前
ajmc.com
Contro mieloma multiplo Lenalidomide rimborsato in Italia nel post-trapianto
2018年6月26日
dire.it
Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-L…
2023年12月21日
onclive.com
Tafasitamab Lenalidomide vs. CIT for Transplant-Ineligible R/R DLBCL
已浏览 354 次2024年9月30日
vumedi.com
Tafasitamab Lenalidomide Therapy in Relapsed/Refractory DLBCL | OncLive
2023年6月26日
onclive.com
Lenalidomide: Uses, Dosage, Side effects, Precautions, Interactions - Dr…
2025年1月24日
medindia.net
1:19
Dr Mateos on Ongoing Research With Cilta-Cel in Newly Diagnosed Multipl…
2025年4月9日
onclive.com
Development of a Low-dose Percutaneous Delivery System Lenal…
10 个月之前
labroots.com
Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalid…
11 个月之前
onclive.com
FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R …
11 个月之前
onclive.com
Novartis' Sandoz Launches Generic Lenalidomide in Europe
2022年2月18日
marketscreener.com
Daratumumab-based quadruplet therapy for transplant-eligible newly …
2024年4月24日
nih.gov
6:31
Medication cost prevents cancer patient from accessing treatment
2 个月之前
kait8.com
Sanofi: positive opinion from CHMP for multiple myeloma
11 个月之前
marketscreener.com
Daratumumab plus lenalidomide/bortezomib/dexametha…
2024年12月3日
nih.gov
Epcoritamab Combination Sets New Standard in Second-Line Follicular L…
4 个月之前
pharmacytimes.com
ASCO 2025 STUDY: New Standard of Care Emerges for Multiple Myeloma …
1 年前
newswise.com
1:58
Expert Highlights Patient-Centered Advantages of Bispecific Antibody T…
4 个月之前
pharmacytimes.com
Iberdomide and the Rise of CELMoDs in Multiple Myeloma | CURE
2 个月之前
curetoday.com
观看更多视频
静态缩略图占位符